Savara Inc
$ 5.27
3.54%
11 Jun - close price
- Market Cap 1,076,893,000 USD
- Current Price $ 5.27
- High / Low $ 5.35 / 4.96
- Stock P/E N/A
- Book Value 0.80
- EPS -0.56
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.40 %
- ROE -0.80 %
- 52 Week High 7.00
- 52 Week Low 1.98
About
Savara Inc. is a lung disease orphan company. The company is headquartered in Austin, Texas.
Analyst Target Price
$10.81
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-12 | 2026-03-13 | 2025-11-12 | 2025-08-13 | 2025-05-13 | 2025-03-27 | 2024-11-12 | 2024-08-12 | 2024-05-09 | 2024-03-07 | 2023-11-09 | 2023-08-10 |
| Reported EPS | 0 | -0.13 | -0.14 | -0.14 | -0.12 | -0.13 | -0.1145 | -0.12 | -0.11 | -0.09 | -0.1 | -0.07 |
| Estimated EPS | -0.1183 | -0.1163 | -0.13 | -0.12 | -0.128 | -0.114 | -0.11 | -0.11 | -0.1 | -0.1 | -0.07 | -0.08 |
| Surprise | 0.1183 | -0.0137 | -0.01 | -0.02 | 0.008 | -0.016 | -0.0045 | -0.01 | -0.01 | 0.01 | -0.03 | 0.01 |
| Surprise Percentage | 100% | -11.7799% | -7.6923% | -16.6667% | 6.25% | -14.0351% | -4.0909% | -9.0909% | -10% | 10% | -42.8571% | 12.5% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: SVRA
2026-06-11 04:39:56
Savara Inc. stockholders recently approved doubling the company's authorized common shares to 600 million, while Chief Financial and Administrative Officer Dave Lowrance announced his departure for health reasons. COO Robert Lutz will assume the CFO role, bringing capital markets experience. These changes give Savara flexibility for equity raises, potentially leading to dilution, which investors should monitor closely given the company's current lack of revenue and ongoing net losses.
2026-06-09 21:40:19
Savara Inc. shareholders have approved an increase in authorized common stock from 300 million to 600 million shares and an additional 18.9 million shares for its incentive plan. The company also announced executive changes, with Robert Lutz appointed as Chief Financial and Operating Officer following David Lowrance's resignation due to health reasons. Other proposals, including director elections and auditor ratification, were also approved at the annual meeting.
2026-06-09 09:39:56
Savara Inc. shareholders approved significant corporate changes including doubling authorized common stock to 600 million shares and increasing shares for its Omnibus Incentive Plan. The company also announced the appointment of Robert Lutz as Chief Financial and Operating Officer, replacing David Lowrance who resigned due to health reasons. These decisions follow recent developments regarding Savara's Phase 3 IMPALA-2 clinical trial for molgramostim and an FDA extension for its biologics license application.
2026-06-08 23:40:19
Savara Inc. (NASDAQ:SVRA) shareholders approved significant corporate changes, including doubling the authorized common stock to 600 million shares and increasing the shares for the 2024 Omnibus Incentive Plan. The company also announced the appointment of Robert Lutz as Chief Financial and Operating Officer, effective July 15, following David Lowrance's resignation due to health reasons. These decisions were made at the annual meeting on June 4 and reflect a period of growth for the biotech firm, which has seen a 107% return over the past year.
2026-06-08 21:40:19
This article provides a list of recent news and announcements concerning Savara Inc. (NASDAQ: SVRA). Key updates include a Chief Financial and Administrative Officer transition, participation in the 2026 Jefferies Global Healthcare Conference, and presentations of new biomarker and long-term efficacy data from the IMPALA-2 Phase 3 clinical trial of Molgramostim. The company also announced new exercise capacity data from the same trial and reported its first-quarter financial results.
2026-06-08 21:40:19
Savara Inc. announced that CFO and Administrative Officer Dave Lowrance will resign on July 15, 2026, due to health reasons. The company will separate the financial and administrative responsibilities, with current COO Robert Lutz stepping into the CFO role. This leadership restructuring aims to ensure continuous effective financial management as Savara advances its biopharmaceutical programs.
